
Sign up to save your podcasts
Or
What did FDA report as the most-cited issues during medical device inspections for the fiscal year of 2020? Understanding the data can help you prepare against making these common, avoidable mistakes during your next quality system inspection.
In this episode of the Global Medical Device Podcast, Jon Speer talks to Mike Drues with Vascular Sciences. Together, Mike and Jon discuss the FDA FY2020 data for medical device quality system inspections and evaluate the top three most cited QSR clauses that resulted in 483 observations.
Some highlights of this episode include:
Memorable quotes from this episode:“When the number of findings is down, is it because we in companies and we as an industry are doing a better job? Or, is it because of something else?” Mike Drues
“Apparently, FDA doesn’t have a mandate or I’ll use the word, permission, or something of that nature, to do remote inspections for med device companies.” Jon Speer
“Our job as medical device professionals is to make sure that the products that we design, develop, manufacture, sell, so on and so forth, they’re as safe and effective as they can possibly be.” Jon Speer
“I have a responsibility, certainly to the patients, to do an investigation when I learn about something.” Jon Speer
“Average regulatory professionals know the rules, but the best ones know the exceptions.” Mike Drues
The Top 10 Most-Cited Issues in FDA FY2020 Medical Device Inspections
FDA - Inspection Observations
FDA - Medical Devices
FDA - Corrective and Preventive Actions (CAPA)
FDA - Form 483 Frequently Asked Questions
FDA - Premarket Notification 510(k)
Code of Federal Regulations (CFR) - Title 21 Part 820
CFR Part 820:30 - Design Controls
The Bleeding Edge Documentary on Netflix
Mike Drues on LinkedIn
Greenlight Guru Academy
MedTech True Quality Stories Podcast
Greenlight Guru YouTube Channel
Greenlight Guru
What did FDA report as the most-cited issues during medical device inspections for the fiscal year of 2020? Understanding the data can help you prepare against making these common, avoidable mistakes during your next quality system inspection.
In this episode of the Global Medical Device Podcast, Jon Speer talks to Mike Drues with Vascular Sciences. Together, Mike and Jon discuss the FDA FY2020 data for medical device quality system inspections and evaluate the top three most cited QSR clauses that resulted in 483 observations.
Some highlights of this episode include:
Memorable quotes from this episode:“When the number of findings is down, is it because we in companies and we as an industry are doing a better job? Or, is it because of something else?” Mike Drues
“Apparently, FDA doesn’t have a mandate or I’ll use the word, permission, or something of that nature, to do remote inspections for med device companies.” Jon Speer
“Our job as medical device professionals is to make sure that the products that we design, develop, manufacture, sell, so on and so forth, they’re as safe and effective as they can possibly be.” Jon Speer
“I have a responsibility, certainly to the patients, to do an investigation when I learn about something.” Jon Speer
“Average regulatory professionals know the rules, but the best ones know the exceptions.” Mike Drues
The Top 10 Most-Cited Issues in FDA FY2020 Medical Device Inspections
FDA - Inspection Observations
FDA - Medical Devices
FDA - Corrective and Preventive Actions (CAPA)
FDA - Form 483 Frequently Asked Questions
FDA - Premarket Notification 510(k)
Code of Federal Regulations (CFR) - Title 21 Part 820
CFR Part 820:30 - Design Controls
The Bleeding Edge Documentary on Netflix
Mike Drues on LinkedIn
Greenlight Guru Academy
MedTech True Quality Stories Podcast
Greenlight Guru YouTube Channel
Greenlight Guru